The Oncology Deep Dive

Why would AstraZeneca pay $2 billion for just 12% of Summit Therapeutics? And why is Lilly's Jaypirca skipping straight to first-line CLL? This week's theme: oncology is done saving its best drugs for later.

In this Monday Morning Oncology Brief, we unpack the three biggest shifts of the week:

🔹 Lilly's Jaypirca (pirtobrutinib) moves to first line in CLL. The FDA approval is backed by an 80% reduction in progression risk versus chemo-immunotherapy in BRUIN CLL-313. It puts pressure on AbbVie's Imbruvica and AstraZeneca's Calquence. But should doctors use their best rescue drug on day one?

🔹 AstraZeneca's $2B Summit deal. A 12% stake de-risks Summit ahead of its November 14 FDA decision and pairs ivonescimab, a PD-1/VEGF bispecific, with AstraZeneca's Claudin 18.2 ADC in GI cancers. A follow-on deal with Daiichi Sankyo extends the strategy to triple-negative breast cancer. Is this AstraZeneca's answer to Merck's Keytruda-plus-ADC playbook?

🔹 Roche's evERA data in the NEJM. Giredestrant + everolimus cut progression risk by 62% in ESR1-mutated ER+/HER2- breast cancer after CDK4/6 inhibitors. It's an all-oral, chemo-free option with no photopsia.

⚡ Rapid fire:

• Lilly exits its Foghorn collaboration on a SMARCA2 degrader.
• Teva wins FDA approval for its Xgeva biosimilar.
• Novocure's tumor-treating fields device gets approved for pancreatic cancer in Japan.
• AstraZeneca and HUTCHMED file savolitinib + Tagrisso in MET-driven lung cancer.

If the best drugs now go first, what happens to the pipeline of second- and third-line rescue therapies?

Subscribe for a new oncology brief every Monday.

#Oncology #CLL #BreastCancer #Pharma #Biotech #AstraZeneca #Lilly #Roche

Chapters:

00:00 Oncology stops saving its best drugs for later

01:09 Lilly's Jaypirca wins frontline FDA approval in CLL

01:41 Superglue vs master key: covalent vs non-covalent BTK inhibitors

02:28 BRUIN CLL-313: 80% lower progression risk vs chemo

03:04 Pressure on AbbVie's Imbruvica and AstraZeneca's Calquence

04:18 The debate: use your best rescue drug on day one?

05:46 AstraZeneca's $2B stake in Summit Therapeutics

06:43 Why a minority stake: de-risking Summit's November FDA decision

07:37 Ivonescimab + Claudin 18.2 ADC: stacking mechanisms in GI cancers

09:09 Taking on Merck's Keytruda + ADC playbook

09:52 Daiichi Sankyo extends the bet to triple-negative breast cancer

10:15 Roche's evERA trial: giredestrant + everolimus

10:57 How oral SERDs shred the estrogen receptor

11:44 62% lower progression risk in ESR1-mutated breast cancer

12:37 No photopsia: Roche's edge over rival oral SERDs

13:53 Rapid fire: Lilly exits Foghorn's SMARCA2 degrader

14:53 Teva's Degevma, a biosimilar to Amgen's Xgeva

15:23 Novocure's tumor-treating fields approved for pancreatic cancer in Japan

16:02 AstraZeneca and HUTCHMED file savolitinib + Tagrisso

16:40 The end of step therapy: what happens to rescue drugs?

In this episode:

🔹 Kidney cancer: FDA approves Merck and Eisai's Welireg + Lenvima after immunotherapy, beating Exelixis' Cabometyx in a Phase 3 trial for the first time. But with more than 70% of patients having severe side effects, is it a real win?

🔹 Multiple myeloma: AbbVie's etentamig posts a record 0.40 hazard ratio with no severe neurotoxicity. J&J fights back by pushing Tecvayli into earlier lines, and BMS's iberdomide doubles MRD negativity as its successor to Revlimid.

🔹 Who decides? Why hospital logistics, payer coverage and infrastructure now shape treatment choices as much as the trial data.

🔹 Rapid fire: Bayer's Nubeqa, Merck's TROP2 antibody-drug conjugate, BeOne's liver cancer bet, and the PD-1/VEGF bispecific race.

Oncology is no longer just pharmacology. It's choreography. But what does "cure" mean when the playbook changes every six months?

#Oncology #CancerResearch #MultipleMyeloma #KidneyCancer #Pharma #Biotech

Disclaimer:AI-generated from publicly available news. Not medical or investment advice. Maycontain errors — verify against primary sources.

00:00 Oncology's sequencing paradox

01:11 Kidney cancer: FDA approves Merck & Eisai's Welireg + Lenvima

01:35 The biology: VHL, HIF-2α and a two-front siege

02:57 LITESPARK-011: dethroning Exelixis' Cabometyx

03:52 The toxicity debate: 71.6% severe side effects

05:33 Overall survival: why missing significance isn't the end

06:36 What's at stake for Eisai, Merck & Bayer

07:02 Multiple myeloma: AbbVie's etentamig at IMS 2026

08:07 Second-gen bispecifics: the "gentle bouncer"

09:26 Record 0.40 hazard ratio & zero severe neurotoxicity

10:25 J&J strikes back: moving Tecvayli into earlier lines

12:34 BMS's iberdomide: hijacking the cell's garbage disposal

14:26 Life after Revlimid: what's riding on it for BMS

15:04 Experts divided: CAR-T vs bispecifics vs CELMoDs

16:04 Hospital logistics now decide treatment

17:43 Rapid fire: Nubeqa, Merck's TROP2 ADC, BeOne, PD-1/VEGF

18:40 From pharmacology to choreography: redefining "cure"

Three stories dominated oncology this week — and each one redefines what it takes to win. First, Eli Lilly's FDA approval of imlunestrant locks down ESR1-mutated breast cancer with a clinical moat that AstraZeneca's failed SERENA-4 trial couldn't crack, while Roche pivots to a tolerability play in early-stage disease. Then, Curium's Bexlutry shatters Novartis's radioligand monopoly using the exact same molecule, proving that in the age of decaying isotopes, logistics can trump R&D. Finally, five CHMP recommendations out of Europe reshape the competitive map — from Enhertu's leap into curative-intent adjuvant therapy to a Keytruda–Padcev combination that slams the door on bladder cancer competitors. Plus a lightning round covering Amgen access wins, GSK's $750M myeloma deal, and a wave of stealth trial registrations signaling a defensive land grab across lung and breast cancer.

Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.

(00:00) Introduction & What's Ahead This Week

(00:52) Lilly's Imlunestrant: FDA Approval & the ESR1 Mutation

(01:38) How Tumors Outsmart Hormone Therapy

(02:30) SERDs: A New Mechanism of Action

(02:53) EMBER-3 Trial Results — Doubling Progression-Free Survival

(03:38) AstraZeneca's SERENA-4 Failure & Lilly's Clinical Moat

(04:46) Roche's Strategic Pivot to Early-Stage Breast Cancer

(05:59) Curium's Bexlutry vs. Novartis's Lutathera

(06:30) How Radioligand Therapies Work

(07:17) The 505(b)(2) Pathway — Regulatory Shortcut or Disruption?

(08:32) The Supply Chain Battle — Decaying Isotopes & Logistics

(10:21) What Bexlutry Means for Radiopharmaceutical Investment

(11:03) Europe's Regulatory Wave — Five CHMP Recommendations

(11:49) Enhertu's Leap from Palliative to Curative Intent

(13:52) PARP Inhibitor Commoditization vs. Market Lock-Out

(15:29) Keytruda + Padcev Corner the Bladder Cancer Market

(16:13) Lightning Round — Five Headlines in Five Minutes

(17:43) Closing: The Evolving Definition of a Commercial Moat

What happens when a cancer drug works exactly as designed — stops the tumor for months — but the patient dies sooner? That paradox runs through the biggest oncology dataweekend of the year.

We distill the data drop from the World Conference on Lung Cancer (WCLC) in Seoul: Ivonescimab beating Keytruda head-to-head in first-line non-small cell lung cancer, theDESTINY-Lung04 survival paradox, two same-day breakthroughs that revived smallcell lung cancer after decades of stagnation, and what the wave of genericsmeans for the oncology "blockbuster."

We cut through the jargon on bispecific antibodies, antibody-drug conjugates, and BiTEs — and why sequencing may now matter as much as the drug itself.

Disclaimer:AI-generated from publicly available news. Not medical or investment advice.May contain errors — verify against primary sources.

00:00 The Survival Paradox

00:32 Welcome to the Deep Dive

01:19 HARMONI-2: Ivonescimab vs Keytruda

02:25 How Bispecific Antibodies Work

03:13 The Survival Numbers

04:18 The Single-Region Trial Caveat

05:18 Merck's Response

06:04 DESTINY-Lung04: The Paradox

06:40 How Antibody-Drug Conjugates Work

08:10 Why the Survival Paradox Happens

09:29 A Curveball: Sevabretinib

11:10 RESILIENT-3: Cullinan vs J&J

14:37 Small Cell: The Graveyard Awakens

16:12 Amgen's BiTE: Molecular Handcuffs

17:09 Sequencing, Not Competing

18:08 Diagnostics & Disease Interception

19:38 Where the Venture Capital Flows

20:22 The Generics Reality Check

21:07 The End of the Blockbuster Era?